A Phase 1b Study of Venetoclax and Capecitabine In Subjects With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Experienced Disease Progression During or After CDK4/6 Inhibitor Therapy
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 4
- 试验地点
- 18
- 主要终点
- Maximum observed plasma concentration (Cmax) of venetoclax
研究概览
简要总结
Endocrine therapy is the initial treatment for most hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancers. This study will evaluate the use of venetoclax in combination with capecitabine in adult participants with HR+, HER2-, metastatic breast cancer (MBC) who had disease progression following treatment that included a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.
Venetoclax is an investigational drug being developed for the treatment of breast cancer. This study is open-label meaning both the participants and study doctors will know what treatment is being given. The study includes two phases: dose escalation and dose expansion. In dose escalation, participants will receive various doses of venetoclax in combination with capecitabine. In dose expansion, participants will receive the recommended dose of venetoclax determined during dose escalation in combination with capecitabine. Adult participants with locally advanced or MBC that is not amenable to curative therapy will be enrolled. Around 42 participants will be enrolled at approximately 20 sites worldwide.
Venetoclax and capecitabine will be administered on a 21-day cycle. During dose escalation, participants will take various doses of venetoclax as a tablet by mouth once a day and capecitabine as a tablet by mouth twice per day on days 1 - 14 of each cycle for approximately 30 weeks. During dose expansion, participants will take venetoclax at the dose identified during dose escalation as a tablet by mouth once a day and capecitabine as a tablet by mouth twice per day on days 1 - 14 of each cycle for approximately 30 weeks.
There may be a higher burden for participants in this trial compared to standard of care. Participants will attend weekly visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and evaluating for side effects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of advanced or metastatic breast cancer that is hormone receptor positive (HR+) and HER2 negative (HER2-).
- •Eastern Cooperative Oncology Group (ECOG) performance score of 0-
- •Willing to provide tissue biopsy sample prior to start of study treatment, and in participants with measurable disease, at Day 1 of Cycle
- •Escalation cohort: Able to provide a tissue sample obtained at any time in disease history prior to start of study treatment.
- •Expansion cohort: Able to provide a fresh tissue sample from either primary tumor or metastatic site; if fresh sample collection is deemed unsafe by the investigator, then an archival tissue block is acceptable if obtained at time of most recent progression and within 16 weeks of study treatment.
- •Experienced disease progression during or after CDK4/6 inhibitor therapy administered in combination with endocrine therapy for a minimum of 8 weeks prior to progression.
排除标准
- •History of receiving systemic cytotoxic chemotherapy in the locally advanced or metastatic setting.
- •Received anti-cancer therapy within the previous 21 days prior to the start of study drugs.
- •No known uncontrolled metastases to the central nervous system (CNS). Participants with brain metastases are eligible provided they have shown positive clinical and radiographic stable disease for at least 4 weeks after definitive therapy and have not used steroids for at least 2 weeks prior to first dose of study drugs.
研究组 & 干预措施
Dose Escalation: Venetoclax and Capecitabine
Venetoclax at various doses will be administered in combination with capecitabine until a recommended dose is determined.
干预措施: Venetoclax (Drug)
Dose Escalation: Venetoclax and Capecitabine
Venetoclax at various doses will be administered in combination with capecitabine until a recommended dose is determined.
干预措施: Capecitabine (Drug)
Dose Expansion: Venetoclax and Capecitabine
Venetoclax at the dose identified in Dose Escalation administered in combination with capecitabine.
干预措施: Venetoclax (Drug)
Dose Expansion: Venetoclax and Capecitabine
Venetoclax at the dose identified in Dose Escalation administered in combination with capecitabine.
干预措施: Capecitabine (Drug)
结局指标
主要结局
Maximum observed plasma concentration (Cmax) of venetoclax
时间窗: Up to 9 days after first dose of study drug
Maximum observed plasma concentration (Cmax) of venetoclax
Maximum observed plasma concentration (Cmax) of capecitabine
时间窗: Up to 9 days after first dose of study drug
Maximum observed plasma concentration (Cmax) of capecitabine.
Maximum observed plasma concentration (Cmax) of 5-fluorouracil
时间窗: Up to 9 days after first dose of study drug
Maximum observed plasma concentration (Cmax) of 5-fluorouracil.
Time to Cmax (peak time, Tmax) of venetoclax
时间窗: Up to 9 days after first dose of study drug
Time to Cmax (peak time, Tmax) of venetoclax.
Time to Cmax (peak time, Tmax) of 5-fluorouracil
时间窗: Up to 9 days after first dose of study drug
Time to Cmax (peak time, Tmax) of 5-fluorouracil.
Time to Cmax (peak time, Tmax) of capecitabine
时间窗: Up to 9 days after first dose of study drug
Time to Cmax (peak time, Tmax) of capecitabine.
Area under the plasma concentration versus time curve (AUC) for venetoclax up to 24 hours post-dose (AUC0-24)
时间窗: Up to 24 hours
Area under the plasma concentration versus time curve for venetoclax up to 24 hours post-dose.
Area under the plasma concentration versus time curve (AUC) for capecitabine/5-fluorouracil up to 12 hours post-dose (AUC0-12)
时间窗: Up to 12 hours
Area under the plasma concentration versus time curve for capecitabine/5-fluorouracil up to 12 hours post-dose.
Number of participants with Dose Limiting Toxicities (DLTs)
时间窗: Up to 21 days after first dose of study drug
Adverse events that are considered by the investigator to have a reasonable possibility of relationship to the administration of venetoclax in combination with capecitabine will be considered a DLT.
次要结局
未报告次要终点